1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
CannLabs, Inc.

CannLabs, Inc.

CANL
CannLabs, Inc.US flagOther OTC
0.00
USD
- -
- -
93,317.00Market Cap
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
TTM
Revenue per Share
- -
- -
- -
0.01
0.01
0.02
0.03
Basic EPS, GAAP
- -
-0.01
-0.01
- -
- -
-0.03
-0.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
-0.03
-0.03
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.07
-0.08
-0.08
-0.08
- -
-0.03
-0.03
Tangible Book Value per Share
- -
- -
- -
- -
- -
-0.03
-0.04
Basic Weighted Avg Shares
16
16
16
17
54
60
62
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
1
2
Operating Margin (%)
-309.97
-155.77
-959.61
-18.11
3.05
-233.57
-250.15
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
-2
-2
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-328.93
-164.41
-961.07
-19
- -
-116.08
-96.18
Working Capital
- -
- -
- -
- -
- -
-1
-2
LT Debt
- -
- -
- -
- -
- -
1
2
Total Equity
- -
- -
- -
- -
- -
-2
-2
Return on Invested Capital (%)
- -
- -
- -
- -
8.42
- -
- -
Return on Capital (%)
- -
- -
- -
- -
1.02
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'14
Dec'14
Mar'15
ST Debt
- -
- -
1
LT Borrowings
- -
1
2
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
65
65
65
Market Capitalization
70
56
91

Working Capital

FRC

•

in mil. unless spec.
Sep'14
Dec'14
Mar'15
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
2
2
Payables & Accruals
1
1
1
ST Debt
- -
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-916.83%
-5,736.19%
Free Cash Flow
- -
1,801.29%
8,662.08%
Net Income, GAAP
- -
- -
5,603.76%
Sales/Revenue/Turnover
- -
287.79%
353.81%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
1
1
2015
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
-0.01
- -
-0.03
2015
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Mark C. Mirken
Full Time Employees
37
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
3888 East Mexico Avenue Denver CO United States of America 80210
IPO Date
Jun 13, 2014
CIK
0001449934
Website
cannlabs.net
Similar Companies
Suven Pharmaceuticals Limited (SUVENPHAR.BO)
MPH Health Care AG (0W1Q.L)
Walvax Biotechnology Co., Ltd. (300142.SZ)
Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK)
Morepen Laboratories Limited (MOREPENLAB.BO)
Hester Biosciences Limited (HESTERBIO.NS)
Business
CannLabs, Inc. (CANL) operates as a cannabis testing laboratory provider in the United States, offering comprehensive analytical services to growers, producers, retailers, and related nutraceutical and pharmaceutical clients; core testing includes potency testing for cannabinoids, residual solvent analysis, microbiological testing, pesticide testing, heavy metals testing, nutrient analysis, terpenes analysis, shelf-life and stability studies, gene expression testing, and genotyping/phenotyping testing, alongside data analytics, consulting, and education services. Founded in 2010 and headquartered in Denver, Colorado, the company serves the healthcare sector's drug manufacturing specialty and generic segment through its 37-employee operations focused on compliance and quality assurance in cannabis products such as flowers, oils, edibles, tinctures, topicals, and beverages. Recent financials reflect trailing twelve-month revenue of $1.72 million with a market capitalization of approximately $94,000 as of late 2025, while historical developments include a Colorado facility closure around 2017, a ticker symbol change to CANL, and past reverse merger announcements with funding commitments, though no major partnerships, acquisitions, or new product launches have been reported in the last 1-2 years.

Company News

APIChat

  • defenseworld.net

    Contrasting NeuroOne Medical Technologies (NASDAQ:NMTC) and Cannlabs (OTCMKTS:CANL)

  • defenseworld.net

    PACS Group (NYSE:PACS) and Cannlabs (OTCMKTS:CANL) Head to Head Analysis